Tag Archive for: uveal melanoma

iOnctura reaches new clinical milestones in uveal melanoma

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall survival compared to historical controls Site activation ongoing for randomized Phase II OCULE-01 study in uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 11 Dec 2024 – […]

iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors • To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers • To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications Geneva, […]

iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ

Roginolisib is in development for solid and hematologic malignancies including uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 31 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that the US Food and Drug Administration (FDA) has granted permission to proceed […]

iOnctura Awarded UK’s MHRA Innovation Passport For Entry Into Innovative Licensing And Access Pathway (ILAP)

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA). Read more…

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in rare ocular cancer to be conducted at MD Anderson Cancer Center─ Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with […]